Please use this identifier to cite or link to this item:
Title: Rituximab : a novel treatment for Pemphigus in Malta
Authors: Boffa, Michelle-Marie
Mintoff, Dillon
Mercieca, Liam
Cassar, David
Cauchi, Suzanne
Boffa, Michael J.
Scerri, Lawrence
Keywords: Pemphigus -- Pathophysiology
Pemphigus -- Treatment
Immune response -- Regulation
Biological response modifiers
Issue Date: 2017-12
Publisher: University of Malta. Medical School
Citation: Boffa, M., Mintoff, D., Mercieca, L., Cassar, D., Cauchi, S., Boffa, M. J., & Scerri, L. (2017). Rituximab : a novel treatment for Pemphigus in Malta. Malta Medical School Gazette, 1(4), 15-22.
Abstract: Until recently, the main treatment for pemphigus has been systemic corticosteroids, usually administered at high doses with consequent side-effects. Lately, the biological agent rituximab has been introduced as an effective treatment for this condition. This article describes seven cases of pemphigus successfully treated with rituximab in Malta and discusses the benefits and drawbacks of this novel treatment modality.
Appears in Collections:MMSG, Volume 1, Issue 4
MMSG, Volume 1, Issue 4
Scholarly Works - FacM&SMed
Scholarly Works - FacM&SPsy

Files in This Item:
File Description SizeFormat 
MMSG 1-4 - A3.pdf1.32 MBAdobe PDFView/Open

Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.